Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)

HTA Council Recommendation (as of 23 November 2022) The HTA Council recommends the government financing of abiraterone acetate (250mg tablet) in combination with prednisone (PD) as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC) through its inclusion in the Philippine National Formulary. Relevant Information Evidence and Relevant Documents Assessment History Back to continue reading : Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)